Clinical Trials
Oncotelic Therapeutics Advances RNA Therapy for High-Unmet-Need Cancers Amid Rising Global Cancer Burden
Oncotelic Therapeutics is developing innovative RNA-based treatments for underserved cancers, addressing the growing global cancer crisis with recently completed phase 1 clinical trials.
Ocumetics Completes One-Month Postoperative Examinations for Revolutionary Intraocular Lens
Ocumetics Technology Corp. has completed critical one-month postoperative examinations for its innovative accommodating intraocular lens, marking a significant milestone in developing a potential vision correction solution that could eliminate the need for glasses or contact lenses.
Lantern Pharma Completes Successful Phase 1a Trial for AI-Driven Cancer Drug LP-184
Lantern Pharma's AI-developed oncology drug LP-184 demonstrates promising safety and efficacy in Phase 1a trial, showing disease control in 48% of evaluable patients with advanced solid tumors and paving the way for targeted cancer treatments.
Hong Kong and GBA Cities Forge Biomedical Partnership Driving Global Innovation Leadership
Hong Kong's biomedical sector has grown nearly 30% in the past decade, with collaborative efforts across the Greater Bay Area positioning the region as a global biotech innovation hub through financial resources, clinical trial capabilities, and cross-border partnerships.
LabConnect and OmniScience Partner to Launch First AI Solution for Real-Time Clinical Lab Data Analysis
LabConnect and OmniScience have partnered to create the first AI-driven platform that provides real-time insights from clinical trial lab data, potentially accelerating drug development timelines and improving trial outcomes.
GeoVax's Multi-Antigen COVID-19 Vaccine Shows Superior Immune Response in CLL Patients Compared to mRNA Vaccines
GeoVax's GEO-CM04S1 vaccine demonstrated significantly better immune response in chronic lymphocytic leukemia patients than standard mRNA vaccines, addressing a critical unmet need in immunocompromised populations.
American Heart Association Launches Major Initiative to Address Treatment Gaps in Common Heart Failure Types
The American Heart Association's new three-year IMPLEMENT-EF initiative aims to improve care for the 75% of heart failure patients with preserved or mildly reduced ejection fraction, addressing significant evidence gaps through multidisciplinary team approaches and real-world data analysis.
Oncotelic Therapeutics Reports Two Years of Clinical Progress Across Oncology and Rare Disease Programs
Oncotelic Therapeutics has achieved significant clinical milestones over the past two years, advancing multiple late-stage programs including OT-101 for pancreatic cancer and OXi4503 for AML/MDS, positioning the company to address multi-billion-dollar markets with high unmet medical needs.
GeoVax's Multi-Antigen COVID-19 Vaccine Shows Strong Immune Response in Immunocompromised Patients
GeoVax Labs' GEO-CM04S1 vaccine demonstrates robust immunity in high-risk patients with blood cancers, potentially addressing a multi-billion dollar market where current vaccines have limited effectiveness.
Spark Biomedical Secures Wellcome Leap Funding to Advance Women's Health Neurostimulation Technology
Spark Biomedical's recent funding from Wellcome Leap will enable FDA-style clinical trials for its OhmBody wearable neurostimulation device, which has shown promising results in reducing menstrual bleeding and symptoms, representing a significant advancement in addressing long-neglected women's health needs.
Cybin Executives to Present at TD Cowen Neuropsychiatry Summit Amid Phase 3 Depression Treatment Development
Cybin Inc. executives will present at the TD Cowen Neuropsychiatry & Epilepsy Summit, highlighting the company's late-stage development of novel mental health treatments including CYB003, which has received FDA Breakthrough Therapy Designation for major depressive disorder.
Kairos Pharma to Host Key Opinion Leader Event on Phase 2 Prostate Cancer Trial Results
Kairos Pharma will present interim efficacy results from its Phase 2 trial of ENV105 in advanced prostate cancer, potentially addressing critical drug resistance challenges in oncology treatment.
Sigyn Therapeutics Appoints Dr. Christoph Zaba to Scientific Advisory Board to Advance Dialysis-Like Cardiovascular Therapy
Sigyn Therapeutics has appointed Dr. Christoph Zaba, an expert in extracorporeal therapies, to its Scientific Advisory Board to support the development of Sigyn Therapy™, a novel treatment designed to reduce cardiovascular disease risk factors using existing dialysis infrastructure.
Oncotelic Therapeutics Engages IBN to Lead Corporate Communications Strategy
Oncotelic Therapeutics has selected IBN to manage its corporate communications as the company advances its RNA-based immunotherapy pipeline, including a Phase 3 pancreatic cancer treatment, highlighting strategic positioning for future clinical and regulatory milestones.
Helix BioPharma to Present Clinical Trial Progress and NASDAQ Uplisting Plans at Investor Summit
Helix BioPharma will present its Phase Ib/II clinical study for non-small cell lung cancer treatment and planned NASDAQ uplisting at the Q3 2025 Investor Summit, highlighting strategic moves to advance oncology therapies and access global capital markets.
Clene Inc. Advances Toward NDA Submission for ALS Therapy CNM-Au8®
Clene Inc. is progressing toward submitting a New Drug Application for its ALS treatment CNM-Au8® by late 2025, potentially offering new hope for patients with this devastating neurodegenerative disease.
VolitionRx Partners with Werfen to Advance Diagnostic Testing for Antiphospholipid Syndrome
VolitionRx has signed an agreement with Werfen to evaluate its Nu.Q NETs assay for improved detection and monitoring of antiphospholipid syndrome, potentially transforming diagnosis and management for millions of patients worldwide.
Gyre Therapeutics Advances Hydronidone Toward China Approval and Expands Clinical Pipeline
Gyre Therapeutics has submitted Hydronidone for approval in China and initiated a U.S. Phase 2 trial, positioning the company for significant growth in liver fibrosis treatment markets.
OS Therapies Advances Toward 2026 Osteosarcoma Drug Launch with FDA RMAT Designation
OS Therapies Inc. achieves critical regulatory milestones for its OST-HER2 immunotherapy, positioning for potential accelerated approval and U.S. commercial launch in 2026 to address a 40-year treatment gap in osteosarcoma.
GeoVax's Multi-Antigen COVID-19 Vaccine Shows Promise for Immunocompromised Patients
GeoVax Labs will present clinical data demonstrating that its GEO-CM04S1 vaccine generates cross-variant antibody and robust cellular immune responses in immunocompromised patients with hematologic malignancies, potentially addressing a critical gap in COVID-19 protection for vulnerable populations.
New Medication Baxdrostat Shows Promise in Lowering Blood Pressure and Slowing Kidney Disease Progression
The novel medication baxdrostat demonstrated significant reductions in systolic blood pressure and urine albumin levels in patients with chronic kidney disease and uncontrolled hypertension, potentially offering new treatment options for this high-risk population.
Soligenix Receives FDA Orphan Drug Designation for Dusquetide in Behçet's Disease Treatment
Soligenix Inc. has secured FDA orphan drug designation for its investigational therapy dusquetide, marking a significant advancement in treating Behçet's disease following promising phase 2a clinical trial results.
Nutriband Secures $5.3 Million Through Warrant Exercises to Advance Abuse-Deterrent Fentanyl Patch Development
Nutriband Inc. has raised $5.3 million from warrant exercises to fund the clinical development and FDA submission of AVERSA Fentanyl, potentially the world's first abuse-deterrent opioid patch with estimated peak annual U.S. sales of $80-200 million.
Cybin Inc. to Present at H.C. Wainwright Global Investment Conference
Cybin Inc. will present at the H.C. Wainwright 27th Annual Global Investment Conference, highlighting its late-stage neuropsychiatry developments including breakthrough therapy-designated treatments for major depressive disorder and generalized anxiety disorder.
Lantern Pharma Receives FDA Guidance for Pediatric CNS Cancer Trial, Advancing AI-Driven Oncology Treatment
Lantern Pharma has completed a Type C meeting with the FDA, gaining regulatory guidance for its planned pediatric trial targeting CNS cancers including ATRT, which could accelerate development of its AI-driven oncology therapy LP-184/STAR-001.
Kairos Pharma to Present Initial Phase 1 Data for ENV105 Lung Cancer Treatment at World Conference
Kairos Pharma Ltd. will present initial Phase 1 data for its ENV105 combination therapy targeting drug-resistant non-small cell lung cancer at the World Lung Cancer Conference, potentially addressing significant unmet medical needs in oncology treatment.
Cybin Inc. to Present at Cantor Global Healthcare Conference, Highlighting Progress in Neuropsychiatric Treatments
Cybin Inc.'s participation in the Cantor Global Healthcare Conference underscores the company's advancing clinical programs for mental health disorders, including its Phase 3 CYB003 for major depressive disorder and Phase 2 CYB004 for generalized anxiety disorder, both of which hold significant potential to address unmet medical needs.
GeoVax to Present Pipeline Updates at H.C. Wainwright Investment Conference
GeoVax Labs will showcase progress on its Mpox/smallpox, COVID-19, and cancer immunotherapy programs at the upcoming H.C. Wainwright conference, highlighting advancements in vaccine development and manufacturing capabilities.
Sigyn Therapeutics Expands Cardiovascular Disease Study to Target Lipoprotein Reduction
Sigyn Therapeutics plans a clinical feasibility study of its blood purification technology that could address cardiovascular disease in high-risk patients while potentially extending lives of end-stage renal disease patients and generating significant economic impact.
Clene Inc. to Present at H.C. Wainwright Global Investment Conference
Clene Inc. will present at the H.C. Wainwright 27th Annual Global Investment Conference, highlighting its late-stage clinical developments in neurodegenerative disease treatments.